Sarcopenia and cancer treatment side effects study
Part of Brain & nervous system, Cancer clinical trials.
This study looks at how muscle loss (sarcopenia) might affect side effects from cancer treatments. If you are starting a new cancer treatment, a CT scan before treatment can help doctors predict your risk of side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a solid tumor cancer (not blood cancer) that has been confirmed by a biopsy.
- You are about to start your first cancer treatment (like chemotherapy, targeted therapy, or immunotherapy).
- You have had a CT or PET scan within 45 days before starting treatment.
- You do not have a pacemaker or defibrillator.
- You are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether doctors can spot “low muscle” (sarcopenia) in everyday clinic care for people with ovarian or endometrial cancer who are planning to start chemotherapy. It may help your care team identify muscle loss early and potentially support better treatment planning.
This study looks at how common muscle weakness (sarcopenia) and thinking or memory changes (often called “chemobrain”) are in people after cancer treatment. It may help teams understand what support could be most helpful after chemotherapy.
This trial looks at muscle loss (called sarcopenia) in people with colon cancer to test an intervention that may help strength or recovery. If you’re age 70 or older and meet the cancer and health requirements, you may be able to take part.
This study looks at how muscle loss (sarcopenia) affects people diagnosed with colorectal cancer before age 50. It uses CT or MRI scans taken at diagnosis to measure muscle mass and see how it relates to treatment and outcomes.
This study looks at how chemotherapy and immunotherapy affect the body in older adults with colorectal cancer, especially early side effects. It may help researchers understand why some people lose strength and how to better predict and manage treatment toxicity.
This study looks at how your body’s “fat-free mass” (mostly muscle and organs) may change the dose of carboplatin and the risk of chemotherapy side effects. It’s for people with advanced lung cancer who are starting treatment with carboplatin plus paclitaxel for the first time.
Hear when a new Sarcopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.